Posted by Michael Wonder on 13 Apr 2022
NICE backs Biogen’s Vumerity for multiple sclerosis
13 April 2022 - Patients with relapsing-remitting multiple sclerosis in England, Wales and Northern Ireland can now access treatment with Biogen’s oral therapy Vumerity, after NICE recommended the drug for routine NHS use.
The decision means that Vumerity (diroximel fumarate) – a follow-up to Biogen’s older oral therapy Tecfidera (dimethyl fumarate) – is now available to eligible patients across the UK, as the SMC approved the drug in February.
